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We previously showed that a prototype gel comprising zinc acetate (ZA) in carrageenan (CG) protected mice against vaginal and
rectal herpes simplex virus 2 (HSV-2) challenge as well as macaques against vaginal simian-human immunodeficiency virus re-
verse transcriptase (SHIV-RT) challenge. In this work, we modified buffers and cosolvents to obtain a stable, nearly iso-osmolal
formulation and evaluated its safety and efficacy against SHIV-RT and HSV-2. In vitro toxicity to lactobacilli and Candida albi-
canswas determined. Macaques were given daily doses of ZA and CG (ZA/CG) or CG alone vaginally for 14 days and challenged
with SHIV-RT 24 h later. Mice were challenged vaginally or rectally with HSV-2 immediately after a single gel treatment to mea-
sure efficacy or vaginally 12 h after daily gel treatment for 7 days to evaluate the gel’s impact on susceptibility to HSV-2 infection.
The modified ZA/CG neither affected the viability of lactobacilli or C. albicans nor enhanced vaginal HSV-2 infection after daily
ZA/CG treatment. Vaginal SHIV-RT infection of macaques was reduced by 66% (P 0.006) whenmacaques were challenged 24
h after the last dose of gel. We observed 60% to 80% uninfected mice after vaginal (P< 0.0001) and rectal (P 0.008) high-dose
HSV-2 challenge. The modified ZA/CG gel is safe and effective in animal models and represents a potential candidate to limit the
transmission of HIV and HSV-2.
Several recent clinical trials have shown that microbicides con-taining antiretroviral drugs (ARVs) reduce the sexual trans-
mission of HIV and other sexually transmitted diseases (STIs) (1).
The Centre for the AIDS Program of Research in South Africa
(CAPRISA) 004 trial (CAPRISA-004) showed that pericoital use
(before and after sex) of vaginally applied 1% tenofovir (TFV) gel
reduced human immunodeficiency virus type 1 (HIV-1) and her-
pes simplex virus 2 (HSV-2) acquisition by 39% and 51%, respec-
tively (2). Similarly, three oral pre-exposure trials (iPrex, Partners
PrEP, and TDF2) targeting men who have sex with men (MSM)
and transgender women, HIV-serodiscordant couples, or hetero-
sexual men and women demonstrated between 44% and 73% ef-
ficacy (1). Conversely, a lack of efficacy was seen in two trials
(FEM-PrEP and VOICE) in which women received daily oral
emtricitabine-TFV and TFV (1, 3). A recent analysis of these two
studies suggested that the lack of efficacy could have been due to
poor regimen adherence (1, 3, 4).
Although ARV-containing topical microbicides will likely be
available soon, there are important questions regarding their use.
(i) Does topical administration of an ARV in people with an un-
diagnosedHIV infection lead to resistance development and affect
their treatment outcomes? (ii) How accessible will these products
be (i.e., will they be available over the counter or by prescription
only)? (iii) Can the introduction of an HIV-specific microbicide
increase the transmission of other STIs?
Given these unanswered questions and the potential limita-
tions of ARV-containing topical microbicides, we are seeking to
develop broad-spectrum, non-ARV-based topical microbicides
that are safe, effective, and accessible (5).We recently reported the
in vivo efficacy against simian-human immunodeficiency virus
reverse transcriptase (SHIV-RT) vaginal challenge of a microbi-
cide gel comprising 50 M MIV-150 (a nonnucleoside reverse
transcriptase inhibitor [NNRTI]), 14 mM zinc acetate dihydrate
(ZA), and 3% carrageenan (CG) (6). This gel significantly pro-
tectedmacaques (89% [P 0.0002 versus the CG placebo]) when
animals were challenged 24 h after the last dose of a 14-day daily
dosing regimen. Moreover, a CG gel containing only 14 mM ZA
(ZA/CG) afforded 70% protection in this model (P 0.017) (6).
Additionally, we have shown that ZA and CG act synergistically to
significantly protect mice (75% to 85% uninfected [P 0.0001])
against high-dose (106 PFU) HSV-2 challenge (7).
In order to advance a non-ARV formulation that has potential
activity against both HIV and HSV-2, we needed to optimize the
buffers and cosolvents of the ZA/CG gel to render them appropri-
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ate for human use and confirm its safety and efficacy in preclinical
models. Our results demonstrate that the modified ZA/CG gel is
safe and effective and support the notion that the gel is a potential
non-ARV microbicide suitable for evaluation in clinical trials.
MATERIALS AND METHODS
Cells and virus culture.Caco-2 cells (ATCC, Rockville, MD) were grown
and differentiated using a BioCoat HTS Caco-2 assay system (BD Biosci-
ences, Bedford, MA) as previously described (7).
Lactobacillus jensenii and Lactobacillus crispatus (ATCC) stocks were
prepared as recommended by the ATCC. Briefly, the stocks were grown in
Lactobacilli MRS broth (Fisher Scientific, Suwanee, GA) for 24 or 48 h at
37°C and 5% CO2. The aliquots of lactobacilli were frozen at 80°C in
Lactobacilli MRS broth containing 15% glycerol (Sigma, St. Louis, MO).
Candida albicans (strain SC5413; ATCC) was propagated weekly by
streaking a yeast extract-peptone-dextrose (YPD) agar (Sigma) plate. A
single colony was picked and incubated in 5 ml of Sabouraud dextrose
broth (SB; Sigma) overnight at 30°C with shaking at 150 rpm.
HSV-2 strain G (ATCC) was propagated in Vero cells (ATCC), and
titers were determined using the plaque formation assay on Vero cells as
previously described (8). Aliquots of virus stock were stored at80°C.
The original SHIV-RT stocks (provided by Disa Bottiger, Medivir AB,
Sweden) were grown in phytohemagglutinin (PHA)-activated human pe-
ripheral blood mononuclear cells (PBMCs). Stock titers were redeter-
mined using the 174xCEM cell line (NIH AIDS Research & Reference
Reagent Program), and the 50% tissue culture infective dose (TCID50)
was calculated using the Reed andMuench formula. The virus was stored
at80°C.
Formulation. (i) CG. For step 1, a 4-liter double planetary mixer
(Charles Ross & Son, Hauppauge, NY) was charged with 2,829 g of sterile
filtered water and 3.923 g of sodium acetate trihydrate (Sigma). The solu-
tion was heated for 5min at 69°C with stirring at 40 rpm. CG (102 g, 3.4%
final concentration) was added, and the mixture was stirred for 3 h at
69°C. For step 2, after the formulation was cooled to 25°C, a solution of 6
g of methyl paraben (Spectrum, Gardena, CA)–60 ml of propylene glycol
(Sigma) was added, and the solution was stirred for an additional 1 h at 40
rpm. The formulation pH was adjusted to 6.8, and the reaction volume
was stirred for 15 min under vacuum conditions to remove bubbles. The
following lot numbers were used in our studies: 110408A525ML and
110512A525MR.
(ii) ZA/CG. For step 1, a protocol similar to that used tomake CGwas
used to generate ZA/CG with the following changes: 894 ml of 10 mM
sodium acetate buffer (pH 6.4) was used. CG (31 g) was added to reach a
final concentration of 3%. A solution of 3 g zinc acetate dihydrate-50 ml
sodium acetate buffer was added, and the solution was stirred for an
additional 20 min at 40 rpm. A mixture of 2 g methyl paraben–20 ml
propylene glycol was used. The following lot numbers were used in our
studies: 110411A707ML, 110609A707ML, and 110609A707MR.
Methyl paraben content, zinc content, and physiochemical properties
(osmolality, pH, simple viscosity) were determined using established
methods (7).
Stability studies. Aliquots (25 g) of gel were stored in 30-ml polypro-
pylene bottles (Qorpak, Bridgeville, PA) under the following conditions:
30°C/65% relative humidity (RH), 40°C/75% RH, and 50°C/ambient hu-
midity. Bottles were removed periodically, and the gel was analyzed for
methyl paraben content, osmolality, pH, viscosity, and zinc content (7).
Transepithelial electrical resistance (TEER). The assay was per-
formed as previously described (9), except that the medium was replaced
on the day of the assay with fresh Dulbecco’s modified Eagle’s medium
(DMEM)without phenol red (Invitrogen, Grand Island, NY) and supple-
mentedwithMITO SerumExtender (BDBiosciences). All formulations
were diluted 1:10 in the media described above, and 300l was applied in
triplicate in the upper chambers. Resistance readings were performed at 0,
2, 4, and 6 h.
In vitro toxicity against lactobacilli andC. albicans.We followed the
procedure described by Moncla et al. (10) to evaluate the impact of
ZA/CG on lactobacillus viability. Briefly, diluted ZA/CG and CG gels and
penicillin/streptomycin (Invitrogen) were prepared in saline solution
with 7.5% fetal bovine serum (FBS) (in addition to a control saline solu-
tion with 7.5% FBS only) and incubated with L. jensenii or L. crispatus at a
density of 2 McFarland units (2  108 bacteria/ml) at 37°C, 5% CO2,
and 98% humidity for 30 min. The samples were then plated on LBS agar
(BDBiosciences) plates and incubated at 37°C, 5%CO2, and 98%humid-
ity for 48 to 72 h. After 48 to 72 h, colonies were quantified in a Colony
Doc-it Imaging station (UVP, Upland, CA). Minimum cidal dilutions
that reduced viability by 99.99% (MCC99.99) were determined (11).
Washed C. albicans yeasts (1.6 105) were incubated with or without
gels for 2 h at 30°C with shaking at 150 rpm in a total volume of 200 l of
SB. Fresh SB (2 ml) was then added to the culture, and 40 l of the
resultingmixture was added to 160l of fresh SB. Thatmixture (100l of
a 1:10 dilution) was streaked on YPD agar plates and incubated at 37°C
overnight, and the numbers of colonies were quantified in a Colony
Doc-it Imaging station. The rest of themixturewas incubated overnight at
30°C with shaking at 150 rpm, and viable yeasts were quantified by trypan
blue exclusion. The lack of differentiated hyphae in the yeast SB cultures
(distinguished by their distinct morphologies) was also verified by light
microscopy. The lactobacilli and C. albicans were considered sensitive to
killing if the formulations cause a viability reduction equal to or greater
than 1 log10 (11).
Macaque treatments and SHIV-RT challenge. Housing and care of
adult female Indian rhesusmacaques (Macacamulatta) compliedwith the
regulations under the AnimalWelfare Act and the Guide for the Care and
Use of Laboratory Animals at the Tulane National Primate Research Cen-
ter (TNPRC; Covington, LA) (12, 13). All studies were approved by the
Animal Care and Use Committee of the TNPRC (OLAW Assurance no.
A4499-01), complied with animal care procedures, and were performed
in a facility fully accredited by the Association for Accreditation of Labo-
ratory Animal Care (AAALAC no. 000594). Veterinarians at the TNPRC
Division of Veterinary Medicine monitored animals regularly to mini-
mize any distress or pain (14). The animals ranged in age from 4 to 12
years and weighed 4 to 10 kg. Animals tested negative for simian type D
retroviruses, simian T cell leukemia virus 1, and simian immunodefi-
ciency virus (SIV) prior to use in the efficacy studies. No more than 10
ml/kg of body weight/month EDTA blood was drawn from the animals at
the indicated time points pre- and post-virus challenge. Preemptive and
postprocedural analgesia were required for procedures that might cause
more than momentary pain or distress in humans undergoing the same
procedures. Five weeks before vaginal virus challenge, animals received a
single 30 mg intramuscular (i.m.) injection of medroxyprogesterone ace-
tate (Depo-Provera [depo]; Pfizer, New York, NY).
depo-treated macaques were atraumatically dosed vaginally with 2 ml
of ZA/CG or CG using a pliable French catheter (Covidien, Mansfield,
MA) for 14 consecutive days. At 24 h after the last application, they were
vaginally challengedwith 0.5ml of 103 TCID50 SHIV-RT (SIVmac239 and
HIV-1HxB2 RT). A supine positionwasmaintained for all animals for 20 to
30 min postchallenge to allow absorption of virus. Monkeys were anes-
thetized with ketamine-HCl (10 mg/kg) or tiletamine-zolazepam (8 mg/
kg) prior to all procedures. Individual animal information is summarized
in Table 1. Blood samples were transported overnight from the TNPRC to
our laboratories at the Population Council for processing and analysis.
Measuring SHIV-RT infection. (i) SIVgag PCR. Peripheral blood
mononuclear cells (PBMCs) were isolated as previously reported (6). Dry
cell pellets (5 106 cells) were frozen and stored at80°C until needed.
Pellets were lysed and nested PCR was performed to determine the pres-
ence of SIV gag DNA (14).
(ii) RT-PCR. Plasma viral RNA copy numbers were determined by
quantitative RT-PCR (15). Animals were defined as infected when103
RNA copies/ml were recorded in at least 2 consecutive samples within the
20-week postinfection follow-up period.
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(iii) SIV Ab responses. SIV-specific antibodies (Abs) were monitored
by enzyme-linked immunosorbent assay (ELISA) (6, 16). Ab positivity
was defined as positive OD values at 4 to 8 weeks postchallenge.
Mouse treatment and HSV-2 challenge. All animal care procedures
compliedwith the regulations detailed under the AnimalWelfare Act (13)
and the Guide for the Care and Use of Laboratory Animals (12). Animal
protocols were reviewed and approved by the Institutional Animal Care
and Use Committee of the Comparative Bioscience Center (CBC) at
RockefellerUniversity. For vaginal applications,micewere depo-treated 7
days prior to gel dosing and challenge. For rectal applications, the animals
were fasted for 24 h and anesthetized (Ketamine/Xylazine) prior to gel and
virus application.
Histological evaluation of the cervicovaginal and rectalmucosae af-
ter single-dose gel application.Mice received gel, Dulbecco’s phosphate
buffered saline (D-PBS), or Gynol II applied vaginally (10 l) or rectally
(20 l). The mice were sacrificed 1, 6, or 24 h later, and vaginal or rectal
tissue was collected, processed, and analyzed as previously described (7).
Vaginal and rectal HSV-2 challenge. As previously described (7), gel
was applied vaginally (10 l) or rectally (20 l) before virus challenge 10
min later with 10 l of HSV-2 strain G (106 PFU/mouse). Placebo (D-
PBS) and CG gel groups were included in all studies. Beginning 4 days
after virus inoculation, mice were examined and scored daily for 20 days
in total. Animals with signs of infection (e.g., hind limb paralysis, ery-
thema, hair loss, and swelling in the vaginal area) were deemed infected
and euthanized.
HSV-2 increased-susceptibility model. As described before (7),
depo-treated mice had 10 l of gel (versus D-PBS, CG, and Gynol II)
applied daily vaginally for 7 days and were challenged 12 h after the last
dose with 10 l of 2 103 PFU of HSV-2 strain G. Mice were examined
and scored as described in the preceding section.
Statistical analyses. Fisher’s exact test was used for statistical compar-
ison of the percentages of SHIV-RT-infected animals in the differently
treated groups as well as in the comparison of signs of infection in the
HSV-2 mouse models (GraphPad Prism 5.02; GraphPad Software, San
Diego, CA). P values  0.05 were taken as statistically significant. In the
macaque studies, we combined real-time control data with that from his-
torical controls as a way of increasing our power to detect a difference
between control and test groups while using fewer controls in each study,
as is commonly done inmacaque studies (17, 18). This is possible because
we consistently observe the same frequency of infection and viremia pro-
file in the real-time control groups across studies (6, 19–22).
RESULTS
ZA/CG is safe in vitro and in vivo. Having previously demon-
strated that a prototype ZA/CG gel was safe and effective in vitro
and in vivo, we developed a modified ZA/CG formulation to ren-
der it suitable for clinical testing by adjusting buffers, cosolvents,
and preservatives. The modified gel contains 14 mM ZA, 3% CG,
10 mM sodium acetate, 2.0% propylene glycol, and 0.2% methyl
paraben and is nearly iso-osmolal (350 to 550 mosmol/kg). Table
2 compares side by side the physicochemical properties of the
modified gel versus prototype gels used in previous studies (6, 7).
We examined the modified ZA/CG gel in a battery of in vitro and
in vivo assays to determine any potential safety concerns that
might have arisen after the optimization process.
Unlike Gynol II, which destroyed the Caco-2 cell monolayer
and reduced TEER values within 30 min, the ZA/CG gel had no
affect on TEER values for up to 6 h (Fig. 1A). Lactobacillus and C.
albicans viability was not affected (1 log10 reduction) after incu-
bation with diluted (1:10) ZA/CG (Fig. 1B and C). Additionally,
by counting the yeasts (Fig. 1C), we verified that C. albicans did
not convert from the unicellular yeast-like form into the patho-
genic multicellular filamentous form.
The HSV-2 susceptibility model in mice was used as an in vivo
functional measurement of safety. By using a suboptimal inocu-
lum of 2  103 PFU that infects only 50% of control (D-PBS-
treated) mice, we can detect significant enhancement of infection
as a result of the pretreatment regimen (7). Neither ZA/CG nor
CG enhanced the susceptibility of mice to vaginal HSV-2 infec-
tion, whereas Gynol II did (P 0.0001; Fig. 2A). Further support
for the idea of mucosal safety was provided by the histological
examination of vaginal and rectal mucosae after gel application,
TABLE 1 Summary of challenged-macaque results
Animal no. Gel
Reactivitya
Plasma viral
loadb
SIV DNA in
PBMCc SIV Abd
GE23 CG   
DD29 CG   
GM30 CG   
IR45 CG   
EF46 CG   
BC84 ZA/CG   
DE94 ZA/CG   
FT48 ZA/CG   
EE72 ZA/CG   
DR51 ZA/CG   
GC25 ZA/CG   
FH27 ZA/CG   
a, reactive;, nonreactive.
b Plasma viral RNA status.
c PBMC SIV DNA was tested from week 2 to week 8.
d ELISA for Abs to SIV was performed at weeks 4 and 8 (compared with baseline).
TABLE 2 Formulation attributes after long-term stability testinga
Property
Prototype
ZA/CG
gel
Modified ZA/
CG gel
Carrageenan content 3.0% 3.1%
Lambda/kappa carrageenan ratio 95:5 60:40
Buffer None 10 mM sodium
acetate
Cosolvent None 2% propylene
glycol
Zinc acetate content (13 to 15 mM) 14 mM 14 mM
Methyl paraben content (0.18 to 0.22 wt %) 0.2 wt % 0.2 wt %
pH (6.9 to 6.3) 6.96 6.64
Osmolality (350–500 mOs/kg) NT 428
Viscosity, t 0 (23,500 to 35,000 cP) 25,300 cP 28,800 cP
Viscosity (3 mos at 30°C/65% RH) NT 30,600 cP
Viscosity (6 mos at 30°C/65% RH) NT 33,300 cP
Viscosity (9 mos at 30°C/65% RH) NT 32,200 cP
Viscosity (12 mos at 30°C/65% RH) NT 34,300 cP
Viscosity (3 mos at 40°C/75% RH) NT 24,500 cP
Viscosity (6 mos at 40°C/75% RH) NT 24,800 cP
Viscosity (9 mos at 40°C/75% RH) NT 23,900 cP
Viscosity (1 mo at 50°C/ambient) NT 30,500 cP
a Formulations were placed in 30-ml polypropylene bottles. The bottles were capped
and sealed and then stored at 30°C/65% RH, 40°C/75% RH, and 50°C/ambient
humidity. The gels were analyzed at indicated times for pH, viscosity, osmolality,
methyl paraben (MP) content, and zinc content. The acceptable ranges for each
parameter are indicated in the Property column. All parameters stayed within
specifications over 12 months at 30°C/65% RH, 9 months at 40°C/75% RH, and 1
month at 50°C/ambient humidity. NT, not tested.
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which revealed, at most, minor epithelial sloughing in the vaginal
and rectal epithelia at 6 h after gel application, with the lamina
propria remaining intact at all time points (Fig. 2B). As expected,
Gynol II damaged the tissues (including exposure of the lamina
propria) within 1 to 6 h of treatment (repaired by 24 h).
ZA/CG significantly reduces vaginal SHIV-RT infection in
macaques. Table 3 summarizes the results obtained in the vaginal
SHIV-RTmicrobicide efficacymacaquemodel using themodified
ZA/CGgel comparedwith published efficacy data of the prototype
ZA/CG gel (6). Studies with the prototype ZA/CG gel showed that
repeated dosing (daily or every other day) provided significant
protection against vaginal SHIV-RT infection when macaques
were challenged 8 to 24 h after the last gel dose (70% protection;
4/21 infected versus 9/14 infected in the CG group; P 0.017) (6),
while a single dose appeared less effective (20). The 70% protec-
tion (4/21 infected) achieved with the prototype gel reflects the
FIG 1 Modified ZA/CG is safe in vitro. (A) Differentiated Caco-2 cell monolayers were treated with 1:10-diluted formulations for 0 to 6 h before TEER values
(triplicates for each sample at each time point) were measured. The graph shows the means	 standard deviations (SD) for each formulation (two independent
experiments). (B) L. jensenii (filled bars) and L. crispatus (empty bars) were treated with 1:10-diluted CG or ZA/CG versus penicillin/streptomycin (P/S) (P, 100
U/ml; S, 100 g/ml) and saline solution with a 7.5% FBS control (to set 100% viability) for 30 min at 37°C, 5% CO2, and 98% humidity. The samples were then
plated in triplicate in LBS agar and incubated at 37°C, 5% CO2, and 98% humidity for 48 to 72 h before counting the colonies. The graph shows means	 SD of
the results of three independent experiments. The SDwas calculated by pooling the results of three replicates from each independent experiment. (C)C. albicans
yeasts (1.6 105) were incubated for 2 h at 30°C in 1:10-diluted CG or ZA/CG versus 50 g/ml amphotericin B (Amph. B) or SB alone. (Left axis [filled bars])
Diluted aliquots were plated on YPD agar plates and cultured overnight at 37°C. The number of colonies was counted for each condition and is shown as the
percentage of colonies relative to the SB control (set as 100%). (Right axis [empty bars]) The samples cultured for 2 h were diluted 40-fold in SB and incubated
overnight at 30°C in a 96-well flat-bottom plate. The numbers of viable yeasts were counted, and the percentages relative to the SB-treated controls are shown.
No multicellular filamentous forms were seen under any condition. Means 	 SD of the results of 5 independent experiments are summarized. The SD was
calculated by pooling the results of three replicates from each independent experiment.
FIG 2 In vivo treatment with ZA/CG does not damage the epithelia. (A) depo-treated BALB/c mice (n 40 per group) were treated daily for 7 days with each
formulation. Twelve hours after the last gel application, mice were challenged with 2 103 PFU of HSV-2 strain G. The percentage of uninfected mice over 21
days is shown for each formulation. There was no significant difference between the ZA/CG, CG, and D-PBS results (P  0.12). A significant difference was
observed in comparisons of Gynol II to D-PBS, ZA/CG, or CG gel (P 0.0001). (B) depo-treated (vaginal dosing) and fasted (rectal dosing) mice had ZA/CG,
D-PBS, or Gynol II applied before the mice were euthanized 1, 6, or 24 h later. The entire reproductive or rectal tract was surgically excised for morphological
analyses. The panels represent a sample of the 6 sections of two or three animals that were tested per formulation for each site. The pictures were obtained with
20 magnification.
Kenney et al.
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combination of different times of gel treatment versus SHIV-RT
challenge. If we take into consideration only the results related to
the conditions used for testing the modified gel (repeated dosing
daily with virus challenge 24 h after last dose), the modified and
prototype gels show the same infection frequency (2 of 7 animals;
Table 3). As with previous CG- or placebo intravaginal ring-
treated animals (6, 19, 21, 22), 3 of 5 animals (60%) in the real-
time CG control group became infected. These real-time CG data
were pooled with historical CG control data, giving a 63% infec-
tion frequency in CG-treated animals (12/19 infected). In con-
trast, the 2 of 7 animals infected after repeated treatment with the
modified ZA/CG gel (Fig. 3A and Table 3) represent 53% protec-
tion compared to CG-treated control results.
The infected animals in all groups showed typical plasma
viremia profiles, with mean peak levels of 4.5 106 (	 5.5 105)
RNA copies/ml 2 to 3 weeks after SHIV-RT challenge and mean
set point viral loads of 2.6 105 (	 1 105) RNA copies/ml being
reached by week 12 (Fig. 3B). Animals designated uninfected
showed no detectable viral RNA over the course of 20 weeks of
follow-up (Table 1 and Fig. 3). Since the infection frequencies in
animals treated with prototype (4/21 infected) versus modified
(2/7 infected) ZA/CG were not significantly different (P 
TABLE 3 Summary of the efficacy data in the SHIV-RT macaque model testing prototype and modified gelsa
Gel Version
No. of
applications
Gel dosing relative
to challenge (h)
Protection vs CG
gel (%)
No. of infected
macaques/no. of
challengedmacaques
P value vs
CG gel
ZA/CGb Prototype 14 daily 8 78 70 1/7 4/21 0.0089
ZA/CGb Prototype 14 daily 24 53 2/7
ZA/CGb Prototype 14 EOD 24 78 1/7
CGb Prototype 14 daily 8–24 N/A 9/14 N/A
ZA/CG Modified 14 daily 24 53 2/7 0.1354
CG Modified 14 daily 8–24 N/A 3/5 N/A
ZA/CG Poolc 14 daily 24 66 6/28 0.006
CG Poold 14 daily 8–24 N/A 12/19 N/A
a EOD, every other day; N/A, not applicable.
b Published data (6).
c Pool of the results obtained with the prototype and modified ZA/CG gel (application adaily or EOD for 14 days, with SHIV-RT challenge 8 to 24 h after the last gel application).
d Pool of the results obtained with the prototype and modified CG gel (application daily for 14 days, with SHIV-RT challenge 8to 24 h after the last gel application).
FIG 3 Repeated dosing of the ZA/CG gel offers protection against vaginal SHIV-RT infection for up to 24 h. ZA/CG (n 7) or CG (n 3 real-time controls that
have been added to 16 historical controls; n 19) was applied daily for 14 days to depo-treatedmacaques before they were challenged vaginally with 103 TCID50
SHIV-RT 24 h later. (A) Plasma viral loads were measured over time (SIV RNA copies/ml of plasma), and each symbol denotes an individual animal. (B)Means
(	 SEM) of SIV RNA copies/ml for the animals that became infected in the two groups. (C) Percent infection in each of the different treatment groups: modified
(mod) data, prototype (proto) data, and the combined data from the modified and prototype (mod/proto) ZA/CG groups versus the CG group are shown. The
number of animals infected versus the number of animals challenged in each group is indicated above each bar.
A Potential Non-ARV Microbicide
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0.5949), we combined the results from the two groups (6/28 ani-
mals infected; 21% infected). With greater power to compare the
infection frequencies in the ZA/CG and CG groups (6/28 versus
12/19 infected), we confirmed that ZA/CG afforded significant
(66%) protection even when we challenged macaques 24 h after
the last gel dose (P 0.006; Fig. 3C). Only infected animals devel-
oped SIV-specific Ab responses (Table 1).
Protection against high-dose vaginal and rectalHSV-2 infec-
tion inmice.Wepreviously showed that the prototype ZA/CG gel
is safe and effectively blocks HSV-2 infection in stringent, high-
viral-dose (106 PFU) vaginal and rectal mouse models (7). We
used this system to determine if the modified ZA/CG was compa-
rably effective against high-dose HSV-2 challenge across the vag-
inal and rectal mucosae. Modified ZA/CG significantly increased
the number of animals without signs of infection after vaginal
(80%,P 0.0001 versusD-PBSorCG) and rectal (60%,P 0.008
and P  0.03 versus D-PBS and CG, respectively) challenge
(Fig. 4).
ZA/CG gel is stable. Having demonstrated that the (freshly
prepared) modified ZA/CG gel was safe and effective, we finally
verified that the formulation remained stable over time. Themod-
ified ZA/CG gel was stable for 12 months at 30°C/65% RH (rela-
tive humidity) and 9months at 40°C/75%RH (Table 2). Temper-
ature-dependent changes in viscosity were evident over time but
remained within the acceptable ranges. Gel rheological measure-
ments of viscosity versus shear rate coupled with computational
modeling have predicted optimal vaginal spreading of gels with
this range of viscosity (7). Samples stored at 30°C/65% RH be-
came more viscous whereas samples stored at 40°C/75% RH be-
came less viscous over time. Even after 1 month at 50°C, ZA/CG
remained stable (Table 2).
To evaluate the effect of prolonged storage on gel efficacy, we
tested ZA/CG aged at 40°C/75% RH for 7 months for its ability to
prevent high-dose HSV-2 infection in mice. The aged ZA/CG re-
tained its activity against high-dose vaginal HSV-2 challenge (P
0.0001 versus CG gel; Fig. 4).
DISCUSSION
We are seeking to develop safe and effective non-ARV microbi-
cides that target HIV and other STIs and that could be used vagi-
nally and rectally to reduce HIV/HSV-2 transmission (5) and po-
tentially limit the selection of ARV-resistant HIV that may
compromise the treatment options. However, the full conse-
quences of usingARV-based preventatives for the potential spread
of drug-resistant viruses are not known, and HIV drug resistance
in the context of prevention could be much less prevalent than in
treatment settings (23, 24).
Differing from the ZA/CG prototype gel, the modified ZA/CG
gel is nearly iso-osmolal and buffered and contains a cosolvent,
making this formulation more suitable for clinical testing. Earlier
we showed that prototype ZA/CG was effective against HSV-2 in
mice and SHIV-RT in macaques. In mice, ZA/CG protected
against high-dose vaginal and rectalHSV-2 infection, and even the
higher dose gel (23 mM ZA) was safe (7). Notably, the ZA/CG
combination was synergistic against HSV-2 (7). CG represents an
excellent delivery vehicle for ZA. It has been shown to be safe and
acceptable in numerous preclinical and clinical studies (7, 19, 22,
25–32) despite contradictory observations using in vitro systems
that CG can enhance HIV infection (22, 33). Additionally, CG
may have activity against HPV (34–36). Because the 14 mM ZA
formulation (but not lower concentrations) afforded efficacy
comparable to that of the 23 mM ZA formulation in mice (7), we
advanced the 14 mM ZA/CG gel for macaque testing. In ma-
caques, ZA/CG reduced vaginal SHIV-RT infection even when
animals were challenged up to 24 h after the last dose of gel was
applied (6, 20). Based on these data, we decided to develop amod-
ified (i.e., safe, effective, and stable) 14 mM ZA/CG gel that we
could advance to clinical testing.
Themodified, nearly iso-osmolal ZA/CG formulation (14mM
ZA, 3.1% CG, 10 mM sodium acetate, 2.0% propylene glycol,
0.2%methyl paraben) is stable for at least 12months at 30°C/65%
RH (and 9 months at 40°C/75% RH). Modified ZA/CG is safe in
vitro and in vivo, showing no lower TEER values after 6 h and only
minor epithelial sloughing. Additionally, modified ZA/CG did
not affect the viability of lactobacilli and C. albicans in vitro. Our
data underscore the promise of this formulation for rectal and
vaginal use. As suggested from the originalmouse studies inwhich
prototype ZA/CG gels were tested and resulted in a significant
increase of mice without signs of infection (vaginal, 75% to 85%;
rectal, 60% to 80%) (7), modified ZA/CG protected mice against
both vaginal (75 to 80% uninfected) and rectal (60% uninfected)
HSV-2 infection. Moreover, modified ZA/CG reduced vaginal
SHIV-RT infection ofmacaques evenwhen the animals were chal-
lenged 24 h after the last dose of gel.
How ZA works against both immunodeficiency viruses and
HSV-2 remains to be fully elucidated. A recent publication has
FIG 4 ZA/CG prevents high-dose HSV-2 infection. depo-treated (vaginal) or fasted (rectal) BALB/c mice were challenged with 106 PFU HSV-2 10 min after
application of the indicated formulations (20 animals per formulation). The aged ZA/CG (7 months at 40°C) was also applied in the vaginal study. The
percentages of uninfected mice over time, based on signs of infection, are shown for each treatment group. ZA/CG gels, including the sample kept at 40°C for 7
months, are significantlymore protective than CG (P 0.0001 for vaginal data and P 0.03 for rectal data) or D-PBS (P 0.0001 for vaginal data and P 0.008
for rectal data).
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shown that Zn2may compete with Mg2 in the active site of the
HIV reverse transcriptase (RT), resulting in the formation of a
stable RT-primer-template complex with diminished catalytic ac-
tivity (37). We (J. A. Fernández-Romero, M. Hsu, and M. Robbi-
ani, unpublished data), and others (6, 7, 20, 38, 39), have demon-
strated that ZA has some antiviral activity in vitro and in vivo.
Specifically, we have observed reduced HIV infection when virus
was either pretreated with ZA or when ZA was added early in the
cycle of replication, possibly supporting the notion that RT may
be a target. Notably, the in vivo activity (especially for repeatedly
applied ZA/CG [6]) appears more pronounced than its in vitro
antiviral effects. Zinc is known to have immunomodulatory prop-
erties and, therefore, ZA may make the mucosal environment
more impermeable to infection by modulating immune function
(38–41). Repeated dosing of ZA may more effectively elicit this
effect to sustain a putative antiviral state. Immunomodulatory
effects of ZA on macaque and human mucosal tissues have been
observed (L. Ouattara, G. Villegas, and N. Teleshova, personal
communication), suggesting that these may contribute to the in
vivo antiviral effects. Increased levels of zinc in tissues may also
result from repeated application of ZA/CG, leading to greater ef-
ficacy (through antiviral and/or immunomodulatory mecha-
nisms). Several papers have shown that zinc salts are active against
HSV-2 laboratory and primary isolates (42, 43). The mode of ac-
tion seems to be related to binding of zinc to the virion surface
glycoproteins, a process that leads to inhibition of virus entry into
target cells (43). Antiviral activity against other pathogens has
been widely documented (44–46).
ZA has been generally recognized as safe (GRAS), and no toxic
effects have been seen in rabbits after daily vaginal dosing with 90
mMZA or zinc sulfate-loaded sponges for 10 days (47, 48). How-
ever, some recent data have shown adverse effects of zinc salts after
nasal or vaginal administration (49, 50). Both studies show these
effects only at extremely high doses (200 mM for vaginal admin-
istration) that far exceed those in our formulation. Furthermore,
our 0.3% ZA/CG formulation (ZA at 3 mg/ml) may release
amounts of zinc much lower than the oral dietary allowances of 8
to 13 mg per day as recommended by the Food and Nutrition
Board (7, 51).
A number of non-ARV formulations are currently in preclin-
ical or clinical testing (5): VivaGel (SPL7013 dendrimer) (52),
Praneen (Polyherbal tablet) (53), Griffithsin (GRFT red algal lec-
tin) (54, 55), aptamers (56, 57), and Mabgel (monoclonal anti-
bodies) (58). ZA/CG, like most of the non-ARV candidates men-
tioned above, is a safe, nearly iso-osmolal formulation with
proven activity against HIV. One advantage of ZA/CG versus
some of the other candidates is the broad spectrum of the activity
(HIV, HSV-2, and potentially HPV). Although VivaGel has
shown a broad spectrum of activity against HIV and HSV-2 sim-
ilar to that of ZA/CG, the potency and durability of the antiviral
effect could be inferior to those of ZA/CG formulations (52, 59–
62). VivaGel has shown anti-SHIV activity when applied only 20
min before challenge with 2,500 TCID50 SHIV89.6P (60), and the
anti-HSV-2 window of protection shows 75% to 88% protection
when applied up to 30 min before and 27% protection when ap-
plied 1 h before HSV-2 at 104 PFU (63). VivaGel is also claimed to
exhibit anti-HPV activity, but there are no published reports
available to compare its activity with the strong in vitro and in vivo
anti-HPV activity of carrageenan (32–34).
The potential broad-spectrum activity of ZA/CG, coupledwith
the low cost, safety, and extended window of protection shown in
macaque studies, positions the ZA/CG formulation as a strong,
non-ARV microbicide candidate that warrants further develop-
ment.
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